Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism

Frontiers in Neuroscience

Volumn , Issue 8 FEB, 2014, Pages

  Dugovic, Christine ^a   Shelton, Jonathan E ^a   Yun, Sujin ^a   Bonaventure, Pascal ^a   Shireman, Brock T ^a   Lovenberg, Timothy W ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Orexin 1; Orexin 2; Rat; Receptor antagonist; REM sleep

Indexed keywords

GSK 1059865; HYPNOTIC AGENT; JNJ 10397049; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; PROTEIN INHIBITOR; SB 649868; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATAPLEXY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RECEPTOR BINDING; MALE; NARCOLEPSY; NONHUMAN; NONREM SLEEP; RAT; REM SLEEP; RISK ASSESSMENT; SLEEP PARAMETERS; SLEEP TIME; WAKEFULNESS;

EID: 84898031525     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2014.00028     Document Type: Article

References (39)

1. Betschart, C., Hintermann, S., Behnke, D., Cotesta, S., Fendt, M., Gee, C. E., et al. (2013). Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J. Med. Chem. 56, 7590-7607. doi: 10.1021/jm4007627
2. Bettica, P., Nucci, G., Pyke, C., Squassante, L., Zamuner, S., Ratti, E., et al. (2012a). Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J. Psychopharmacol. 26, 1058-1070. doi: 10.1177/0269881111408954
3. Bettica, P., Squassante, L., Groeger, J. A., Gennery, B., Winsky-Sommerer, R., and Dijk, D. J. (2012b). Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 37, 1224-1233. doi: 10.1038/npp.2011.310
4. Bettica, P., Squassante, L., Zamuner, S., Nucci, G., Danker-Hopfe, H., and Ratti, E. (2012c). The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 35, 1097-1104. doi: 10.5665/sleep.1996
5. Black, S. W., Morairty, S. R., Fisher, S. P., Chen, T. M., Warrier, D. R., and Kilduff, T. S. (2013). Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 36, 325-336. doi: 10.5665/sleep.2442
6. Bourgin, P., Huitron-Resendiz, S., Spier, A. D., Fabre, V., Morte, B., Criado, J. R., et al. (2000). Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J. Neurosci. 20, 7760-7765.
7. Brisbare-Roch, C., Dingemanse, J., Koberstein, R., Hoever, P., Aissaoui, H., Flores, S., et al. (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 13, 150-155. doi: 10.1038/nm1544
8. Carter, M. E., Brill, J., Bonnavion, P., Huguenard, J. R., Huerta, R., and De Lecea, L. (2012). Mechanism for Hypocretin-mediated sleep-to-wake transitions. Proc. Natl. Acad. Sci. U.S.A. 109, E2635-E2644. doi: 10.1073/pnas.1202526109
9. Clark, E. L., Baumann, C. R., Cano, G., Scammell, T. E., and Mochizuki, T. (2009). Feeding-elicited cataplexy in orexin knockout mice. Neuroscience 161, 970-977. doi: 10.1016/j.neuroscience.2009.04.007
10. De Lecea, L., Kilduff, T. S., Peyron, C., Gao, X., Foye, P. E., Danielson, P. E., et al. (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U.S.A. 95, 322-327. doi: 10.1073/pnas.95.1.322
11. Di Fabio, R., Pellacani, A., Faedo, S., Roth, A., Piccoli, L., Gerrard, P., et al. (2011). Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorg. Med. Chem. Lett. 21, 5562-5567. doi: 10.1016/j.bmcl.2011.06.086
12. Dugovic, C., Shelton, J. E., Aluisio, L. E., Fraser, I. C., Jiang, X., Sutton, S. W., et al. (2009). Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J. Pharmacol. Exp. Ther. 330, 142-151. doi: 10.1124/jpet.109.152009
13. Dugovic, C., Yun, S., Shelton, J., Bonaventure, P., Shireman, B., and Lovenberg, T. (2012). Respective role of orexin-1 and orexin-2 receptors in the effects of a dual ox1/2r antagonist on sleep. Sleep 35, A32.
14. Espana, R. A., McCormack, S. L., Mochizuki, T., and Scammell, T. E. (2007). Running promotes wakefulness and increases cataplexy in orexin knockout mice. Sleep 30, 1417-1425.
15. Gotter, A. L., Webber, A. L., Coleman, P. J., Renger, J. J., and Winrow, C. J. (2012). international union of basic and clinical pharmacology. LXXXVI. orexin receptor function, nomenclature and pharmacology. Pharmacol. Rev. 64, 389-420. doi: 10.1124/pr.111.005546
16. Gozzi, A., Turrini, G., Piccoli, L., Massagrande, M., Amantini, D., Antolini, M., et al. (2011). Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS ONE 6:e16406. doi: 10.1371/journal.pone.0016406
17. Herring, W. J., Snyder, E., Budd, K., Hutzelmann, J., Snavely, D., Liu, K., et al. (2012). Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79, 2265-2274. doi: 10.1212/WNL.0b013e31827688ee
18. Hoever, P., Dorffner, G., Benes, H., Penzel, T., Danker-Hopfe, H., Barbanoj, M. J., et al. (2012). Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin. Pharmacol. Ther. 91, 975-985. doi: 10.1038/clpt.2011.370
19. Hong, Z. Y., Huang, Z. L., Qu, W. M., and Eguchi, N. (2005). Orexin A promotes histamine, but not norepinephrine or serotonin, release in frontal cortex of mice. Acta Pharmacol. Sin. 26, 155-159. doi: 10.1111/j.1745-7254.2005.00523.x
20. Lu, J., Sherman, D., Devor, M., and Saper, C. B. (2006). A putative flip-flop switch for control of REM sleep. Nature 441, 589-594. doi: 10.1038/nature04767
21. Mang, G. M., Durst, T., Burki, H., Imobersteg, S., Abramowski, D., Schuepbach, E., et al. (2012). The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 35, 1625-1635. doi: 10.5665/sleep.2232
22. Marcus, J. N., Aschkenasi, C. J., Lee, C. E., Chemelli, R. M., Saper, C. B., Yanagisawa, M., et al. (2001). Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 435, 6-25. doi: 10.1002/cne.1190
23. McAtee, L. C., Sutton, S. W., Rudolph, D. A., Li, X., Aluisio, L. E., Phuong, V. K., et al. (2004). Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg. Med. Chem. Lett. 14, 4225-4229. doi: 10.1016/j.bmcl.2004.06.032
24. Mieda, M., Hasegawa, E., Kisanuki, Y. Y., Sinton, C. M., Yanagisawa, M., and Sakurai, T. (2011). Differential roles of orexin receptor-1 and-2 in the regulation of non-REM and REM sleep. J. Neurosci. 31, 6518-6526. doi: 10.1523/JNEUROSCI.6506-10.2011
25. Mochizuki, T., Arrigoni, E., Marcus, J. N., Clark, E. L., Yamamoto, M., Honer, M., et al. (2011). Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice. Proc. Natl. Acad. Sci. U.S.A. 108, 4471-4476. doi: 10.1073/pnas.1012456108
26. Morairty, S. R., Revel, F. G., Malherbe, P., Moreau, J. L., Valladao, D., Wettstein, J. G., et al. (2012). Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS ONE 7:e39131. doi: 10.1371/journal.pone.0039131
27. Nishino, S. (2007). Clinical and neurobiological aspects of narcolepsy. Sleep Med. 8, 373-399. doi: 10.1016/j.sleep.2007.03.008
28. Nishino, S., and Mignot, E. (1997). Pharmacological aspects of human and canine narcolepsy. Prog. Neurobiol. 52, 27-78. doi: 10.1016/S0301-0082(96)00070-6
29. Oishi, Y., Williams, R. H., Agostinelli, L., Arrigoni, E., Fuller, P. M., Mochizuki, T., et al. (2013). Role of the medial prefrontal cortex in cataplexy. J. Neurosci. 33, 9743-9751. doi: 10.1523/JNEUROSCI.0499-13.2013
30. Peyron, C., Tighe, D. K., Van Den Pol, A. N., De Lecea, L., Heller, H. C., Sutcliffe, J. G., et al. (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996-10015.
31. Sakurai, T. (2007). The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat. Rev. Neurosci. 8, 171-181. doi: 10.1038/nrn2092
32. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., et al. (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585. doi: 10.1016/S0092-8674(00)80949-6
33. Saper, C. B., Chou, T. C., and Scammell, T. E. (2001). The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 24, 726-731. doi: 10.1016/S0166-2236(00)02002-6
34. Scammell, T. E., Willie, J. T., Guilleminault, C., and Siegel, J. M. (2009). A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 32, 111-116.
35. Smith, M. I., Piper, D. C., Duxon, M. S., and Upton, N. (2003). Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci. Lett. 341, 256-258. doi: 10.1016/S0304-3940(03)00066-1
36. Steiner, M. A., Gatfield, J., Brisbare-Roch, C., Dietrich, H., Treiber, A., Jenck, F., et al. (2013). Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem 8, 898-903. doi: 10.1002/cmdc.201300003
37. Willie, J. T., Chemelli, R. M., Sinton, C. M., Tokita, S., Williams, S. C., Kisanuki, Y. Y., et al. (2003). Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 38, 715-730. doi: 10.1016/S0896-6273(03)00330-1
38. Winrow, C. J., Gotter, A. L., Cox, C. D., Doran, S. M., Tannenbaum, P. L., Breslin, M. J., et al. (2011). Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J. Neurogenet. 25, 52-61. doi: 10.3109/01677063.2011.566953
39. Winrow, C. J., and Renger, J. J. (2014). Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br. J. Pharmacol. 17, 283-293. doi: 10.1111/bph.12261